Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019
|
| gptkbp:ATCCode |
L04AA45
|
| gptkbp:contraindication |
active serious infection
|
| gptkbp:developedBy |
gptkb:AbbVie
|
| gptkbp:eliminationHalfLife |
9-14 hours
|
| gptkbp:form |
extended-release tablet
15 mg 30 mg |
| gptkbp:genericName |
gptkb:upadacitinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rinvoq
|
| gptkbp:indication |
gptkb:Crohn's_disease
gptkb:atopic_dermatitis gptkb:psoriatic_arthritis ulcerative colitis rheumatoid arthritis ankylosing spondylitis |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:mechanismOfAction |
JAK inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionRequired |
https://www.rinvoq.com/
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache upper respiratory tract infection increased risk of infection |
| gptkbp:bfsParent |
gptkb:AbbVie
|
| gptkbp:bfsLayer |
6
|